Toledo OH 非小细胞肺癌临床试验
17项针对 非小细胞肺癌的研究正在 Toledo及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- Mercy Health - Perrysburg Cancer Center /ID# 270536, Perrysburg · 距离 8 英里
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
招募中3 期
- ProMedica Flower Hospital, Sylvania · 距离 9 英里
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- Mercy Health - Saint Anne Hospital, Toledo
- Mercy Health - Perrysburg Hospital, Perrysburg · 距离 8 英里
- ProMedica Flower Hospital, Sylvania · 距离 9 英里
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
招募中1 期
- Site 06, Maumee · 距离 9 英里
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
招募中3 期
- Taylor Cancer Research Center, Maumee · 距离 9 英里
Pan-tumor MRD Study
招募中观察性研究
- Taylor Cancer Research Center, Maumee · 距离 9 英里
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
招募中3 期
- Research Site, Toledo
- Research Site, Maumee · 距离 9 英里
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
招募中观察性研究
- Toledo Clinic Cancer Center, Toledo
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
招募中2 期
- Mercy Health - Saint Anne Hospital, Toledo
- Mercy Health - Perrysburg Hospital, Perrysburg · 距离 8 英里
- ProMedica Flower Hospital, Sylvania · 距离 9 英里
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
招募中1/2 期
- Taylor Cancer Research Center, Maumee · 距离 9 英里
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- Research Site, Maumee · 距离 9 英里
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- ProMedica Flower Hospital, Sylvania · 距离 9 英里
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
招募中2/3 期
- ProMedica Flower Hospital, Sylvania · 距离 9 英里
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- ProMedica Flower Hospital, Sylvania · 距离 9 英里
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
招募中1/2 期
- Taylor Cancer Research Center, Maumee · 距离 9 英里
GEMINI-NSCLC: NSCLC Biomarker Study
招募中观察性研究
- Taylor Cancer Research Center, Maumee · 距离 9 英里
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
招募中1/2 期
- Taylor Cancer Research Center (site 204), Maumee · 距离 9 英里
其他城市的 非小细胞肺癌试验
- Houston, TX145 项研究
- New York City, NY121 项研究
- Arlington, VA104 项研究
- Nashville, TN97 项研究
- Boston, MA90 项研究
- Los Angeles, CA87 项研究
- St. Louis, MO73 项研究
- Chicago, IL61 项研究
- Baltimore, MD60 项研究
- San Antonio, TX59 项研究
- Columbus, OH57 项研究
- Washington, DC55 项研究
Toledo的其他研究
- 卵巢癌12 项研究
- 肺癌11 项研究
- 转移性癌症10 项研究
- 卒中9 项研究
- 头颈鳞状细胞癌8 项研究
- 子宫内膜癌8 项研究
- 黑色素瘤8 项研究
- 胰腺癌8 项研究
- 前列腺癌7 项研究
- 食管癌7 项研究
- 缺血性卒中7 项研究
- 心力衰竭7 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。